Noninvasive Genotyping and Assessment of Treatment Response in Diffuse Large B Cell Lymphoma by Florian Scherer, David M. Kurtz, Aaron M. Newman, Henning.

Slides:



Advertisements
Similar presentations
Lymphoma dissemination: the other face of lymphocyte homing by Steven T. Pals, David J. J. de Gorter, and Marcel Spaargaren Blood Volume 110(9):
Advertisements

A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies by Jutta Deckert, Peter U. Park,
Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome by Jacob H. Rand,
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications by Elias Campo, Steven H. Swerdlow, Nancy L.
Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases by Porcia T. Bradford, Susan S. Devesa, William F. Anderson,
Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas by Amrita Krishnan, Arturo Molina, John Zaia, David.
Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene by Xiaoou Zhou,
Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs)‏ by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.
Lenalidomide augments actin remodeling and lowers NK- cell activation thresholds by Kathryn Lagrue, Alex Carisey, David J. Morgan, Rajesh Chopra, and Daniel.
by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald
Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells by Jonathan M. Irish,
Diffuse Large B-Cell Lymphoma (DLBCL) Patients Failing Second-Line R-DHAP Or R-ICE Chemotherapy Included In The Coral Study by Eric Van Den Neste, Christian.
The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.
Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen.
A Prospective Randomized Trial of Buffy Coat Versus CD34-Selected Autologous Bone Marrow Support in High-Risk Breast Cancer Patients Receiving High-Dose.
TCR-MHC-peptide(s): in vivo veritas
Improving academic leadership and oversight in large industry-sponsored clinical trials: the ARO-CRO model by Neil A. Goldenberg, Alex C. Spyropoulos,
Minimal Residual Disease Measurement By Deep Sequencing Reflects Changes In Disease Load During Therapy In Diffuse Large B Cell Lymphoma Patients by Nina.
Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma by Nicolaus Kröger,
Next-generation leukemia immunotherapy
Dasatinib induces complete remission in a patient with primary cerebral involvement of B-cell chronic lymphocytic leukemia failing chemotherapy by Georg.
A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.
Tax fingerprint in adult T-cell leukemia
Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy by Chun.
The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for Readmission Following Autologous Stem Cell Transplant for Lymphoma and.
How I treat elderly patients with myeloma
Nonmyeloablative conditioning for relapsed follicular lymphoma
Superior Survival after Autologous vs
Mechanisms of HIV-associated lymphocyte apoptosis
by Satish Gopal, William A. Wood, Stephanie J. Lee, Thomas C
TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome: a proposal of the International Society for.
A population-based study of cardiac morbidity among Hodgkin lymphoma patients with preexisting heart disease by Sten Myrehaug, Melania Pintilie, Lingsong.
Genetic sequence analysis of inherited bleeding diseases
Mutation Analysis of the Rearranged Immunoglobulin Heavy Chain Genes of Marginal Zone Cell Lymphomas Indicates an Origin From Different Marginal Zone B.
Relationship of p53, bcl-2, and Tumor Proliferation to Clinical Drug Resistance in Non-Hodgkin's Lymphomas by Wyndham H. Wilson, Julie Teruya-Feldstein,
by Jessica A. Reese, Xiaoning Li, Manfred Hauben, Richard H
by Alexander Röth, Andreas Hüttmann, Russell P
Blood Volume 92(10): November 15, 1998
by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle
Evaluation Of Myeloablative Therapy Followed By Autologous Stem Cell Transplantation In First Remission In Patients With Advanced Stage Follicular Lymphoma.
Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma by Weiyun Z. Ai, Robert Tibshirani, Behnaz.
by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald
Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma by Hannes Kaufmann, Markus Raderer, Stefan Wöhrer,
Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience by Daryl Tan, Sandra.
by George Z. Rassidakis, Mauricio P. Oyarzo, and L. Jeffrey Medeiros
Anergy: the CLL cell limbo
Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.
Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma by Pier Luigi Zinzani, Vincent.
HAVEN 2 Updated Analysis: Multicenter, Open-Label, Phase 3 Study to Evaluate Efficacy, Safety and Pharmacokinetics of Subcutaneous Administration of Emicizumab.
by Santosh L. Saraf, Xu Zhang, Tamir Kanias, James P. Lash, Robert E
by H. Ddungu, M. Waiswa, R. Kruisselbrink, P. Kagoma, and M. Crowther
by Wendy Lim, Sara K. Vesely, and James N. George
Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Primary End Point Analysis of the Phase 2 Keynote-087 Study by Craig H. Moskowitz, Pier.
Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naive Patients Aged ≥65 Years with Acute Myeloid Leukemia by Andrew Wei, Stephen.
Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.
Final Results of the Chrysalis Trial: A First-in-Human Phase 1/2 Dose-Escalation, Dose-Expansion Study of Gilteritinib (ASP2215) in Patients with Relapsed/Refractory.
Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor Ibrutinib in Patients with Hairy Cell Leukemia: Stage 1 Results of a Phase 2 Study by Jeffrey.
Bigger, Stronger, Faster: Chimeric Antigen Receptor T Cells Are Olympic Killers by Paul J Neeson, Alexander James Davenport, Joseph A Trapani, Michael.
Resistance mechanism for ibrutinib in marginal zone lymphoma
Temporal analysis of clonal evolution in typical FL and matched TFL samples. Temporal analysis of clonal evolution in typical FL and matched TFL samples.
CR-rate ratios with 95% CIs
Mesenchymal Stem Cell-Derived Vesicles Reverse Hematopoietic Radiation Damage by Sicheng Wen, Laura R Goldberg, Mark S Dooner, John L Reagan, and Peter.
Hepatosplenic T-Cell Lymphoma: Clinicopathological Features and Treatment Outcomes: Report From The North American Peripheral T-Cell Lymphoma Consortium.
by Holbrook E Kohrt, Idit Sagiv-Barfi, Sarwish Rafiq, Sarah E. M
A Novel Risk Assessment Model to Predict Venous Thromboembolism (VTE) in Cancer Inpatients: The Canclot Score by Dana E. Angelini, M. Todd Greene, Julie.
by Chatree Chai-Adisaksopha, Davide Matino, and Alfonso Iorio
Chimeric antigen receptor–modified T cells: CD19 and the road beyond
by Victor A. Chow, Mazyar Shadman, and Ajay K. Gopal
Is Skull-Base to Proximal Thigh PET/CT Enough
Leukemia Stem Cells Are Characterized By CLEC12A Expression and Chemotherapy Refractoriness That Can be Overcome By Targeting with Chimeric Antigen Receptor.
Presentation transcript:

Noninvasive Genotyping and Assessment of Treatment Response in Diffuse Large B Cell Lymphoma by Florian Scherer, David M. Kurtz, Aaron M. Newman, Henning Stehr, Chih Long Liu, Li Zhou, Alexander F.M. Craig, Jacob J. Chabon, Alexander F. Lovejoy, Daniel M. Klass, Cynthia Glover, Robert S. Ohgami, Christian A. Kunder, Brendan C. Visser, George Poultsides, Ronald Levy, Maximilian Diehn, and Ash A. Alizadeh Blood Volume 126(23): December 3, 2015 ©2015 by American Society of Hematology

Florian Scherer et al. Blood 2015;126:114 ©2015 by American Society of Hematology

Florian Scherer et al. Blood 2015;126:114 ©2015 by American Society of Hematology

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.